James Caress, MD
Clinical Neurophysiology · Winston Salem, NCNPI 1184600264
Payments from drug & device makers
What this record shows
This record is dominated by other: $23,200 of the $24,163 with a category attached, or 96.0%. Philips North America LLC accounts for 96.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $11,879 and has fallen 97.6% since, to $282 in 2025.
Across 26 payments — averaging $929.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$23K
- Biogen$574
- Tanabe Pharma America, Inc.$127
- Argenx US, Inc.$123
- Amylyx Pharmaceuticals, Inc.$104
- CSL Behring$24
- plus $13 from 1 others
Across 49 payments — averaging $8555.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mitsubishi Tanabe Pharma Development America, Inc.$159K
- Orion Corporation$148K
- Amylyx Pharmaceuticals, Inc.$39K
- UCB SA$21K
- Catalyst Pharmaceuticals, Inc.$19K
- Biohaven Pharmaceutical Holding Company Ltd.$18K
- plus $16K from 1 others
What the payments were for
- Food & beverage$9504%
- Education$130%
- Other$23,20096%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 4 | $23,200 |
| Biogen | 8 | $574 |
| Tanabe Pharma America, Inc. | 4 | $127 |
| Argenx US, Inc. | 1 | $123 |
| Amylyx Pharmaceuticals, Inc. | 2 | $104 |
| CSL Behring | 1 | $24 |
| Travere Therapeutics, Inc. | 6 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (3237) CA Undiv$23,200
- SPINRAZA$136
- VYVGART$123
How this compares
Too few clinical neurophysiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 219 | $3,044,185 |
| FirdapseAmifampridine Phosphate | 13 | $553,236 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 37 | $492,866 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 24 | $295,750 |
| Riluzole | 174 | $32,801 |
| Azathioprine | 32 | $4,154 |
| Pyridostigmine Bromide | 34 | $2,283 |
| Mexiletine Hcl | 38 | $2,195 |
| Mycophenolate Mofetil | 20 | $1,977 |
| Glycopyrrolate | 38 | $1,309 |
| Prednisone | 122 | $790 |
| Gabapentin | 67 | $687 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $263 |
| Amitriptyline Hcl | 18 | $248 |
| Baclofen | 24 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $24 | $492,86637 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $104 | $295,75024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Winston Salem
- Jane BoggsWinston Salem$555
- Muhammad ZafarDurham$144K
- Christa SwisherCharlotte$39K
- Matthew LuedkeDurham$7K
- Vishal MandgeDurham$4K
- Adrian HadionoConcord$2K
- Christopher ConnellyConcord$431
- Jennifer ZuroskyCharlotte$404
- Betty StewartHendersonville$54
- Prabhu EmmadyConcord$54
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.